Arthur F Ryan sold $82k of REGN
director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $817.30, traded Dec 1, 2023, filed Dec 4, 2023.
Score components
- +15RoleDirector
- +9Trade size$82k at market
- 0Share of holdings soldSold 0.5% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001968202-23-000044, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -1 | $809.03 | $809 | 18,546 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -7 | $810.77 | $5,675 | 18,539 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -27 | $811.48 | $22k | 18,512 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -3 | $812.58 | $2,438 | 18,509 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -4 | $813.35 | $3,253 | 18,505 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -1 | $814.78 | $815 | 18,504 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -3 | $815.46 | $2,446 | 18,501 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -4 | $816.52 | $3,266 | 18,497 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -6 | $817.52 | $4,905 | 18,491 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -2 | $818.76 | $1,638 | 18,489 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -7 | $819.62 | $5,737 | 18,482 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -9 | $820.50 | $7,385 | 18,473 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -2 | $821.92 | $1,644 | 18,471 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -1 | $822.49 | $822 | 18,470 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -6 | $823.36 | $4,940 | 18,464 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -3 | $824.66 | $2,474 | 18,461 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -2 | $825.38 | $1,651 | 18,459 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -10 | $826.62 | $8,266 | 18,449 | Dec 4, 2023 |
| Dec 1, 2023 | SOpen-market sale Common Stock10b5-1 | -2 | $827.61 | $1,655 | 18,447 | Dec 4, 2023 |
Related signals
Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $340k 400 shares | -40% | |
| 33Weak | REGENERON PHARMACEUTICALS, INC. | Marion McCourt EVP Commercial | $2.0M 2,346 shares | -16% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Kathryn Guarini director | $320k 400 shares | -40% | |
| 18Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $640k 800 shares | -32% | |
| 6Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $130k 200 shares | -1% | |
| 3Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $71k 100 shares | -1% | |
| 4Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $78k 100 shares | -1% | |
| 12Weak | REGENERON PHARMACEUTICALS, INC. | Arthur F Ryan director | $79k 100 shares | -1% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Huda Y Zoghbi director | $1.3M 1,638 shares | -49% | |
| 30Weak | REGENERON PHARMACEUTICALS, INC. | Jason Pitofsky SVP Controller | $1.6M 2,036 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.